Track record · closed signal

Merck & Co., Inc. (MRK) — closed signal from September 10, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on December 9, 2025 — +16.2% at the close.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted

$80.01 – $80.97Entry zone — fair-value band

$82.70Published — price the day we called it

$89.32Target — the price the thesis aimed for

$104.94Peak — highest point inside the window, not a realized return

$96.07Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 63 days.

At window close

+16.2%

realized, from the publication price to the last close inside the window

Peak gain

+26.9%

peak, from the publication price — not a realized return

S&P 500, same window

+5%

SPY over the identical days, dividend-adjusted

Window close

$96.07

last close inside the window, ended December 9, 2025

Peak price

$104.94

peak on November 25, 2025 — not a realized return

Days to target

The thesis — published September 10, 2025

Predicted growth

+10%

over the measurement window

Target price

$89.32

the price the thesis aimed for

Entry zone

$80.01 – $80.97

the fair-value band we waited for

Price at publication

$82.70

published September 10, 2025

Confidence

67%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Merck looks set for a short-term recovery as recent price action calms and buyer interest improves. Investor mood is decent, but government policy news is creating noise. Talk of possible White House limits on China-invented medicines adds uncertainty, yet Merck's broad drug lineup and steady cash help limit downside. With easing interest rates, a 0-3 month move back toward typical price levels seems reasonable if risk is managed well.

Primary drivers

The stock pulled back, and signs suggest more buyers may now be stepping in
Strong, steady cash generation helps the business hold up in rough times
Government policy headlines, especially on China drugs, could pressure shares
Falling interest rates can make steady, dependable companies more appealing

How it played out

MRK: target reached in 63 days

On 2025-09-10, Lyra published a short-term MRK thesis at 82.70 with expected growth of 10%. The thesis pointed to calmer recent price action, improving buyer interest, steady cash generation, possible pressure from government policy headlines on China-invented medicines, and lower interest rates making dependable companies more appealing.

Inside the 2025-09-10 to 2025-12-09 window, MRK reached the 89.32 target in 63 days. The peak was 104.94 on 2025-11-25, a 26.9% gain. It ended at 96.07. The published thesis played out, because the stock reached the target and stayed above it at the end.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals